What is Larimar Therapeutics, Inc.'s (LRMR) StockRank?

MoatMap's StockRank for Larimar Therapeutics, Inc. (LRMR) is 23/100, with a Sell signal. This is a composite score combining Quality (31), Value (37), and Momentum (46) factor ranks across MoatMap's 19,000+ stock universe.

Does Larimar Therapeutics, Inc. have an economic moat?

Larimar Therapeutics, Inc. (LRMR) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Larimar Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Larimar Therapeutics, Inc. (LRMR) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Larimar Therapeutics, Inc. in?

Larimar Therapeutics, Inc. (LRMR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

LRMR

SELLREMOVE

Larimar Therapeutics, Inc. · Healthcare · United States · $363M · Avg Vol: $7M/d

StockRank

P/E (TTM)

—

ROE

-109.8%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Larimar Therapeutics is a clinical-stage biotech company. It is highly speculative, pre-revenue, and lacks the structural moat, cash flows, or CDMO manufacturing scale required for our concentrated global fund.

COMPANY DESCRIPTION

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare and severe diseases, with its primary candidate targeting Friedreich's ataxia. The company possesses proprietary technology and intellectual property around its therapeutic candidates for specific orphan diseases, addressing unmet medical needs. Larimar is a development-stage biotech firm with significant R&D risk and potential for substantial upside if clinical trials succeed.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	CAGR
Revenue	0	0	0	0	—
EPS	-2.95	-1.37	-0.84	-1.32	—
Shares	18M	43M	44M	64M	+260.3%
Debt	6M	5M	6M	5M	-5.2%
Equity	64M	111M	82M	172M	38.7%
Op CF	-42M	-28M	-33M	-71M	—
Inv CF	24M	-91M	33M	-85M	—
Fin CF	20M	75M	30,000	162M	—

PRICE (1M)-14.9%

SMA 50SMA 200

$3.59

RSI (14)

53.8

52W High

$6.42

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-212.8%1.6

ROE

-109.8%7.1

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-48.9%4.7

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.02x81.3

Current Ratio

4.29x65.8

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.0x64.3

P/FCF

—N/A

P/B

2.3x50.2

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

56%32.8

RS 6M

-19%57.0

SMA 50/200

1.01x64.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+42%50.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$363M

P/E (Forward)

-2.8x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LRMR are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
LRMR	Larimar Therapeutics, Inc.(you)	$363M	23	SELL
RCKT	Rocket Pharmaceuticals, Inc.	$330M	21	SELL
RZLT	Rezolute, Inc.	$315M	21	SELL
NVCT	Nuvectis Pharma, Inc.	$270M	22	SELL
ARMP	Armata Pharmaceuticals, Inc.	$298M	26	SELL
ENTA	Enanta Pharmaceuticals, Inc.	$385M	28	SELL
GLSI	Greenwich LifeSciences, Inc.	$402M	28	SELL
REPL	Replimune Group, Inc.	$386M	16	STRONG SELL
SGMT	Sagimet Biosciences Inc.	$449M	27	SELL
BNTC	Benitec Biopharma Inc.	$397M	29	SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Larimar Therapeutics, Inc. (LRMR) — Stock Score Summary

Larimar Therapeutics, Inc. (LRMR) has a MoatMap StockRank of 23/100 based on Quality (31/100), Value (37/100), and Momentum (46/100) factor scores. The current signal is SELL. Larimar Therapeutics is a clinical-stage biotech company. It is highly speculative, pre-revenue, and lacks the structural moat, cash flows, or CDMO manufacturing scale required for our concentrated global fund.

Key Financial Metrics

Price	$3.59
Market Cap	$363M
P/E (Forward)	-2.83
Price/Book	2.29
Return on Equity	-109.8%
Return on Invested Capital	-212.8%
Debt/Equity	2.39
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-71M

Larimar Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Larimar Therapeutics, Inc.’s (LRMR) StockRank?: MoatMap’s StockRank for Larimar Therapeutics, Inc. (LRMR) is 23/100, with a Sell signal. It is a composite of Quality (31), Value (37), and Momentum (46) factor ranks across MoatMap’s 19,000+ stock universe.
Does Larimar Therapeutics, Inc. have an economic moat?: Larimar Therapeutics, Inc. (LRMR) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Larimar Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Larimar Therapeutics, Inc. (LRMR) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Larimar Therapeutics, Inc. in?: Larimar Therapeutics, Inc. (LRMR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).